Who is sponsoring NCT05899725?

NCT05899725 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT05899725?

Interventions in NCT05899725: Corticosteroids, Corticosteroids and Ruxolitinib.

What condition does NCT05899725 study?

NCT05899725 studies Severe Checkpoint Inhibitor Pneumonitis.

Is NCT05899725 still recruiting?

NCT05899725 is currently status unknown. Last updated 26 March 2024.

Last reviewed 2024-03-26 · How we verify

NCT05899725

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia

Status unknown NA Last updated 26 March 2024

What this trial tests

NA trial testing Corticosteroids in Severe Checkpoint Inhibitor Pneumonitis in 60 participants. Status unknown.

Timeline

14 April 2023

Primary endpoint
1 March 2025

30 June 2025

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	14 April 2023
Primary completion	1 March 2025
Estimated completion	30 June 2025
Sites	1 location across China

Drugs / interventions tested

Corticosteroids (corticosteroids) — full drug profile →
Corticosteroids and Ruxolitinib — full drug profile →

Conditions studied

Severe Checkpoint Inhibitor Pneumonitis — all drugs for Severe Checkpoint Inhibitor Pneumonitis →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 15 to 80, any sex, with Severe Checkpoint Inhibitor Pneumonitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective multicenter randomized controlled Interventional study, to assess the clinical efficacy and safety of corticosteroids compared to corticosteroids in combination with Ruxolitinib in the treatment of severe checkpoint inhibitor pneumonitis.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review).
Hu X, Ren J, Xue Q, Luan R, et al · · 2023 · cited 12× · PMID 37681488 · DOI 10.3892/ijo.2023.5570
Clinical management of checkpoint inhibitor pneumonitis: Focus, challenges, and future directions.
Xu Y, Chen R, Pan R, Gao X, et al · · 2025 · cited 4× · PMID 40226598 · DOI 10.1016/j.pccm.2024.12.001
Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.
Abdel-Wahab N, Suarez-Almazor ME. · · 2024 · cited 4× · PMID 38400840 · DOI 10.1080/1744666x.2024.2323966

Verify or expand the search:

Other trials of Corticosteroids

Trials testing the same drug.

NCT07297914 — Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL · Phase 2, PHASE3 · not yet recruiting
NCT07340723 — Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) · Phase 2 · recruiting
NCT07565844 — Intradermal Exosomes, Platelet-Rich Plasma, and Steroids for Post-Herpetic Neuralgia · NA · recruiting
NCT06585774 — A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease · Phase 3 · recruiting
NCT06388564 — A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia · Phase 2 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05899725 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 26 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05899725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing